3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
8
Carcinoma, Non-Small-Cell Lung
7
Triple Negative Breast Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasm Metastasis
2
Melanoma
2
Lung Neoplasms
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myelomonocytic, Acute
2
Leukemia, Myeloid, Acute
2
Carcinoma, Renal Cell
2
Urinary Bladder Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Pinealoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Ovarian Diseases
1
Neuroendocrine Tumors
1
Myeloproliferative Disorders
1
Mammary Neoplasms, Animal
1
Lymphoma
1
Leukemia, Promyelocytic, Acute
1
Leukemia, Monocytic, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Erythroblastic, Acute
1
Kidney Neoplasms
1
Hodgkin Disease
1
Fallopian Tube Neoplasms
1
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
1
Interventions
exemestane
1
entinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Mammary Neoplasms, Animal
×
entinostat
×
Clear all
NCT00676663
2022-05-11
ENCORE301
Syndax Pharmaceuticals
Phase 2
Completed
130 enrolled
18 charts